Thrombus formation with rehydrated, lyophilized platelets. 2002

Thomas H Fischer, and Elizabeth P Merricks, and Author P Bode, and Dwight A Bellinger, and Karen Russell, and Robert Reddick, and William E Sanders, and Timothy C Nichols, and Marjorie S Read
Department of Pathology, 350 Old Fayetteville Road, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA.

Stored human platelets are frequently used in hemorrhagic emergencies, but have limited immediate utility for controlling bleeding due to storage lesion and are frequently contaminated with microorganisms. The development of paraformaldehyde-treated, lyophilized and rehydrated (RL) platelets, which are sterile and have a prolonged shelf life (years), ameliorate the efficacy and sterility problems with stored platelets. RL platelets have been shown to have many native functions of fresh platelets in vitro and to mediate hemostasis in vivo in large animal models of hemorrhagic shock and cardiopulmonary bypass induced platelet dysfunction. To further evaluate the functional properties of this transfusion product, we studied the role of RL platelets in three aspects of thrombus formation and lysis. First, the interaction between RL platelets and fibrinogen was investigated. The surface density of unligated GPIIb-IIIa on RL and fresh platelets were, respectively 30000 and 70000 molecules per cell as detected with the monoclonal antibody 10E-5. Freezing, lyophilization and rehydration steps in the preparation of RL platelets resulted in the surface presentation of 120000 molecules of fibrinogen per cell from alpha granule sources. After ADP activation, RL platelets bound exogenous 125I-labeled fibrinogen in a dose-dependent manner with an affinity that is similar to that of fresh platelets and was inhibited by RGD peptides. 125I-Labeled fibrinogen binding to RL and fresh platelets, respectively, saturated at 14000 and 32000 molecules per cell. Scanning electron microscopic ultrastructural analysis showed that fibrin strands interacted with the surface of RL platelets in a normal manner. The second set of studies investigated the ability of RL platelets to catalyze and amplify the clot formation process in an activation-dependent manner. We showed that RL platelets undergo degranulation in fibrin in clots and functioned as thrombogenic surfaces for the generation of activated coagulation factors and fibrin generation. A final set of studies was performed to investigate fibrin of clots that contained RL platelets. RL platelet clots were lysed in the presence of tissue plasminogen activator with a similar time course as clots without platelets, and lysis occurred faster than when fresh platelets were included in the fibrin mass. The results of these three studies demonstrate that RL platelets are capable of mediating thrombus formation and do not inhibit lysis. Our results help explain how RL platelets restore hemostasis in vivo, and indicate that these cells might be a viable alternative to fresh stored platelets in transfusion medicine.

UI MeSH Term Description Entries
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D001793 Blood Preservation The process by which blood or its components are kept viable outside of the organism from which they are derived (i.e., kept from decay by means of a chemical agent, cooling, or a fluid substitute that mimics the natural state within the organism). Blood Preservations,Preservation, Blood,Preservations, Blood
D005337 Fibrin A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot. Antithrombin I
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D005612 Freeze Drying Method of tissue preparation in which the tissue specimen is frozen and then dehydrated at low temperature in a high vacuum. This method is also used for dehydrating pharmaceutical and food products. Lyophilization,Drying, Freeze,Dryings, Freeze,Freeze Dryings,Lyophilizations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013927 Thrombosis Formation and development of a thrombus or blood clot in BLOOD VESSELS. Atherothrombosis,Thrombus,Blood Clot,Blood Clots,Thromboses
D015550 Cell Degranulation The process of losing secretory granules (SECRETORY VESICLES). This occurs, for example, in mast cells, basophils, neutrophils, eosinophils, and platelets when secretory products are released from the granules by EXOCYTOSIS. Degranulation, Cell

Related Publications

Thomas H Fischer, and Elizabeth P Merricks, and Author P Bode, and Dwight A Bellinger, and Karen Russell, and Robert Reddick, and William E Sanders, and Timothy C Nichols, and Marjorie S Read
May 2008, Platelets,
Thomas H Fischer, and Elizabeth P Merricks, and Author P Bode, and Dwight A Bellinger, and Karen Russell, and Robert Reddick, and William E Sanders, and Timothy C Nichols, and Marjorie S Read
November 2006, Transfusion,
Thomas H Fischer, and Elizabeth P Merricks, and Author P Bode, and Dwight A Bellinger, and Karen Russell, and Robert Reddick, and William E Sanders, and Timothy C Nichols, and Marjorie S Read
April 1993, Transfusion,
Thomas H Fischer, and Elizabeth P Merricks, and Author P Bode, and Dwight A Bellinger, and Karen Russell, and Robert Reddick, and William E Sanders, and Timothy C Nichols, and Marjorie S Read
January 1995, Proceedings of the National Academy of Sciences of the United States of America,
Thomas H Fischer, and Elizabeth P Merricks, and Author P Bode, and Dwight A Bellinger, and Karen Russell, and Robert Reddick, and William E Sanders, and Timothy C Nichols, and Marjorie S Read
May 1978, British medical bulletin,
Thomas H Fischer, and Elizabeth P Merricks, and Author P Bode, and Dwight A Bellinger, and Karen Russell, and Robert Reddick, and William E Sanders, and Timothy C Nichols, and Marjorie S Read
January 1971, The Journal of pharmacology and experimental therapeutics,
Thomas H Fischer, and Elizabeth P Merricks, and Author P Bode, and Dwight A Bellinger, and Karen Russell, and Robert Reddick, and William E Sanders, and Timothy C Nichols, and Marjorie S Read
June 2010, AAPS PharmSciTech,
Thomas H Fischer, and Elizabeth P Merricks, and Author P Bode, and Dwight A Bellinger, and Karen Russell, and Robert Reddick, and William E Sanders, and Timothy C Nichols, and Marjorie S Read
January 1998, Memorias do Instituto Oswaldo Cruz,
Thomas H Fischer, and Elizabeth P Merricks, and Author P Bode, and Dwight A Bellinger, and Karen Russell, and Robert Reddick, and William E Sanders, and Timothy C Nichols, and Marjorie S Read
January 1982, Nihon rinsho. Japanese journal of clinical medicine,
Thomas H Fischer, and Elizabeth P Merricks, and Author P Bode, and Dwight A Bellinger, and Karen Russell, and Robert Reddick, and William E Sanders, and Timothy C Nichols, and Marjorie S Read
January 2022, Frontiers in oncology,
Copied contents to your clipboard!